Skip to main content

Table 1 Information on mesenchymal stem cells derived from ovarian cancer patients

From: Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer

Sample ID

Disease

Process timing

Grams of Fat Processed

Karyotype (see footnote)

1

Newly Diagnosed

Immediate

0.95

Normal

3

Newly Diagnosed

Immediate

0.16

Abnormal1

4

Newly Diagnosed

Immediate

2.26

Normal

7

Newly Diagnosed

Immediate

3.96

Normal

8

Newly Diagnosed

43 hours

3.40

Normal

10

Newly Diagnosed

Immediate

0.80

Normal

2

Relapsed

14 hours

2.23

Normal

5a

Relapsed

Immediate

1.50

Normal

5b

Relapsed

20 hours

1.60

Abnormal2

6

Relapsed

11 hours

1.79

Normal

  1. 1Of 20 metaphases, 16 were normal and 4 had trisomy 20.
  2. 2Of 30 metaphases, 28 were normal and 2 had trisomy 20 and a balanced three-way translocation involving chromosomes 1, 10 and 13.
  3. Adipose tissues were either processed immediately or stored in the refrigerator at 4°C before collagenase digestion. Expanded MSC were karyotyped and two out of ten samples were found to have abnormal karyotype.